Rates of first event by treatment, mutational status, and previous event at diagnosis
| Treatment . | Event . | All Patients with MF . | JAK2 mutation . | Triple negative . | Previous arterial event . | Previous venous event . | Previous major bleeding . |
|---|---|---|---|---|---|---|---|
| All patients | AE | 2.28 (105/46.0; 1079) | 2.74 (62/22.6; 549) | 1.77 (26/14.7; 260) | 5.15 (45/8.7; 268) | 4.20 (13/3.1; 86) | 4.09 (13/3.2; 92) |
| VTE | 0.96 (45/47.1; 1079) | 1.13 (26/23.1; 549) | 0.72 (11/15.2; 260) | 1.16 (11/9.5; 268) | 2.48 (8/3.2; 86) | 1.81 (6/3.3; 92) | |
| MajBl | 2.27 (105/46.3; 1079) | 2.46 (56/22.8; 549) | 1.80 (27/15.0; 260) | 2.83 (26/9.2; 268) | 4.42 (14/3.2; 86) | 3.66 (12/3.3; 92) | |
| No treatment | AE | 2.49 (45/18.1; 750) | 2.63 (20/7.6; 366) | 2.64 (18/6.8; 206) | 7.40 (20/2.7; 179) | 8.38 (8/1.0; 54) | 3.07 (4/1.3; 64) |
| VTE | 0.75 (14/18.7; 750) | 0.91 (7/7.7; 366) | 0.55 (4/7.2; 206) | 1.34 (4/3.0; 179) | 1.86 (2/1.1; 54) | 0.72 (1/1.4; 64) | |
| MajBl | 2.28 (42/18.4; 750) | 2.24 (17/7.6; 366) | 1.97 (14/7.1; 206) | 2.03 (6/3.0; 179) | 4.79 (5/1.0; 54) | 2.20 (3/1.4; 64) | |
| Hydroxyurea | AE | 2.02 (40/19.8; 672) | 2.70 (30/11.1; 392) | 1.10 (6/5.4; 144) | 3.66 (17/4.6; 185) | 3.62 (5/1.4; 54) | 4.01 (5/1.2; 53) |
| VTE | 1.15 (23/20.0; 672) | 1.23 (14/11.4; 392) | 1.13 (6/5.3; 144) | 1.04 (5/4.8; 185) | 3.64 (5/1.4; 54) | 3.26 (4/1.2; 53) | |
| MajBl | 1.95 (39/20.0; 672) | 2.46 (28/11.4; 392) | 0.74 (4/5.4; 144) | 3.43 (16/4.7; 185) | 2.08 (3/1.4; 54) | 5.54 (7/1.3; 53) | |
| Interferon | AE | 0.37 (1/2.7; 82) | 1.19 (1/0.8; 38) | 0.00 (0/1.2; 23) | 0.00 (0/0.2; 10) | 0.00 (0/0.3; 10) | 0.00 (0/0.0; 2) |
| VTE | 0.37 (1/2.7; 82) | 1.19 (1/0.8; 38) | 0.00 (0/1.2; 23) | 0.00 (0/0.2; 10) | 0.00 (0/0.3; 10) | 0.00 (0/0.0; 2) | |
| MajBl | 0.74 (2/2.7; 82) | 1.17 (1/0.9; 38) | 0.83 (1/1.2; 23) | 0.00 (0/0.2; 10) | 0.00 (0/0.3; 10) | 0.00 (0/0.0; 2) | |
| JAK inhibitors | AE | 3.89 (17/4.4; 238) | 5.19 (14/2.7; 145) | 1.22 (1/0.8; 43) | 5.41 (6/1.1; 52) | 2.07 (1/0.5; 21) | 3.73 (2/0.5; 25) |
| VTE | 1.63 (7/4.3; 238) | 1.51 (4/2.6; 145) | 2.53 (2/0.8; 43) | 1.78 (2/1.1; 52) | 2.40 (1/0.4; 21) | 1.78 (1/0.6; 25) | |
| MajBl | 5.05 (21/4.2; 238) | 4.15 (11/2.6; 145) | 8.77 (6/0.7; 43) | 2.69 (3/1.1; 52) | 7.31 (3/0.4; 21) | 3.57 (2/0.6; 25) | |
| IMiDs | AE | 2.27 (1/0.4; 55) | 0.00 (0/0.3; 27) | 8.02 (1/0.1; 17) | 0.00 (0/0.1; 10) | 0.00 (0/0.0; 3) | 19.71 (1/0.1; 6) |
| VTE | 0.00 (0/0.5; 55) | 0.00 (0/0.3; 27) | 0.00 (0/0.1; 17) | 0.00 (0/0.1; 10) | 0.00 (0/0.0; 3) | 0.00 (0/0.1; 6) | |
| MajBl | 4.36 (2/0.5; 55) | 7.73 (2/0.3; 27) | 0.00 (0/0.1; 17) | 15.92 (1/0.1; 10) | 85.34 (1/0.0; 3) | 0.00 (0/0.1; 6) | |
| ESAs | AE | 2.56 (12/4.7; 308) | 2.70 (6/2.2; 160) | 1.19 (2/1.7; 78) | 3.84 (4/1.0; 72) | 2.49 (1/0.4; 34) | 9.35 (3/0.3; 35) |
| VTE | 0.85 (4/4.7; 308) | 0.90 (2/2.2; 160) | 0.59 (1/1.7; 78) | 0.92 (1/1.1; 72) | 2.49 (1/0.4; 34) | 3.08 (1/0.3; 35) | |
| MajBl | 3.43 (16/4.7; 308) | 2.70 (6/2.2; 160) | 4.22 (7/1.7; 78) | 1.90 (2/1.1; 72) | 5.07 (2/0.4; 34) | 3.07 (1/0.3; 35) |
| Treatment . | Event . | All Patients with MF . | JAK2 mutation . | Triple negative . | Previous arterial event . | Previous venous event . | Previous major bleeding . |
|---|---|---|---|---|---|---|---|
| All patients | AE | 2.28 (105/46.0; 1079) | 2.74 (62/22.6; 549) | 1.77 (26/14.7; 260) | 5.15 (45/8.7; 268) | 4.20 (13/3.1; 86) | 4.09 (13/3.2; 92) |
| VTE | 0.96 (45/47.1; 1079) | 1.13 (26/23.1; 549) | 0.72 (11/15.2; 260) | 1.16 (11/9.5; 268) | 2.48 (8/3.2; 86) | 1.81 (6/3.3; 92) | |
| MajBl | 2.27 (105/46.3; 1079) | 2.46 (56/22.8; 549) | 1.80 (27/15.0; 260) | 2.83 (26/9.2; 268) | 4.42 (14/3.2; 86) | 3.66 (12/3.3; 92) | |
| No treatment | AE | 2.49 (45/18.1; 750) | 2.63 (20/7.6; 366) | 2.64 (18/6.8; 206) | 7.40 (20/2.7; 179) | 8.38 (8/1.0; 54) | 3.07 (4/1.3; 64) |
| VTE | 0.75 (14/18.7; 750) | 0.91 (7/7.7; 366) | 0.55 (4/7.2; 206) | 1.34 (4/3.0; 179) | 1.86 (2/1.1; 54) | 0.72 (1/1.4; 64) | |
| MajBl | 2.28 (42/18.4; 750) | 2.24 (17/7.6; 366) | 1.97 (14/7.1; 206) | 2.03 (6/3.0; 179) | 4.79 (5/1.0; 54) | 2.20 (3/1.4; 64) | |
| Hydroxyurea | AE | 2.02 (40/19.8; 672) | 2.70 (30/11.1; 392) | 1.10 (6/5.4; 144) | 3.66 (17/4.6; 185) | 3.62 (5/1.4; 54) | 4.01 (5/1.2; 53) |
| VTE | 1.15 (23/20.0; 672) | 1.23 (14/11.4; 392) | 1.13 (6/5.3; 144) | 1.04 (5/4.8; 185) | 3.64 (5/1.4; 54) | 3.26 (4/1.2; 53) | |
| MajBl | 1.95 (39/20.0; 672) | 2.46 (28/11.4; 392) | 0.74 (4/5.4; 144) | 3.43 (16/4.7; 185) | 2.08 (3/1.4; 54) | 5.54 (7/1.3; 53) | |
| Interferon | AE | 0.37 (1/2.7; 82) | 1.19 (1/0.8; 38) | 0.00 (0/1.2; 23) | 0.00 (0/0.2; 10) | 0.00 (0/0.3; 10) | 0.00 (0/0.0; 2) |
| VTE | 0.37 (1/2.7; 82) | 1.19 (1/0.8; 38) | 0.00 (0/1.2; 23) | 0.00 (0/0.2; 10) | 0.00 (0/0.3; 10) | 0.00 (0/0.0; 2) | |
| MajBl | 0.74 (2/2.7; 82) | 1.17 (1/0.9; 38) | 0.83 (1/1.2; 23) | 0.00 (0/0.2; 10) | 0.00 (0/0.3; 10) | 0.00 (0/0.0; 2) | |
| JAK inhibitors | AE | 3.89 (17/4.4; 238) | 5.19 (14/2.7; 145) | 1.22 (1/0.8; 43) | 5.41 (6/1.1; 52) | 2.07 (1/0.5; 21) | 3.73 (2/0.5; 25) |
| VTE | 1.63 (7/4.3; 238) | 1.51 (4/2.6; 145) | 2.53 (2/0.8; 43) | 1.78 (2/1.1; 52) | 2.40 (1/0.4; 21) | 1.78 (1/0.6; 25) | |
| MajBl | 5.05 (21/4.2; 238) | 4.15 (11/2.6; 145) | 8.77 (6/0.7; 43) | 2.69 (3/1.1; 52) | 7.31 (3/0.4; 21) | 3.57 (2/0.6; 25) | |
| IMiDs | AE | 2.27 (1/0.4; 55) | 0.00 (0/0.3; 27) | 8.02 (1/0.1; 17) | 0.00 (0/0.1; 10) | 0.00 (0/0.0; 3) | 19.71 (1/0.1; 6) |
| VTE | 0.00 (0/0.5; 55) | 0.00 (0/0.3; 27) | 0.00 (0/0.1; 17) | 0.00 (0/0.1; 10) | 0.00 (0/0.0; 3) | 0.00 (0/0.1; 6) | |
| MajBl | 4.36 (2/0.5; 55) | 7.73 (2/0.3; 27) | 0.00 (0/0.1; 17) | 15.92 (1/0.1; 10) | 85.34 (1/0.0; 3) | 0.00 (0/0.1; 6) | |
| ESAs | AE | 2.56 (12/4.7; 308) | 2.70 (6/2.2; 160) | 1.19 (2/1.7; 78) | 3.84 (4/1.0; 72) | 2.49 (1/0.4; 34) | 9.35 (3/0.3; 35) |
| VTE | 0.85 (4/4.7; 308) | 0.90 (2/2.2; 160) | 0.59 (1/1.7; 78) | 0.92 (1/1.1; 72) | 2.49 (1/0.4; 34) | 3.08 (1/0.3; 35) | |
| MajBl | 3.43 (16/4.7; 308) | 2.70 (6/2.2; 160) | 4.22 (7/1.7; 78) | 1.90 (2/1.1; 72) | 5.07 (2/0.4; 34) | 3.07 (1/0.3; 35) |
Data in the table are reported as rate (number of events/patient time; number of patients), in which time is measured in 100-year units.
AE, arterial event; ESAs, erythropoietin-stimulating agents; IMiDs, immunomodulatory drugs; MajBl, major bleeding; VTE, venous thromboembolism.